TEVETEN Drug Patent Profile
✉ Email this page to a colleague
When do Teveten patents expire, and when can generic versions of Teveten launch?
Teveten is a drug marketed by Abbvie and is included in two NDAs.
The generic ingredient in TEVETEN is eprosartan mesylate; hydrochlorothiazide. There are eleven drug master file entries for this compound. Additional details are available on the eprosartan mesylate; hydrochlorothiazide profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TEVETEN?
- What are the global sales for TEVETEN?
- What is Average Wholesale Price for TEVETEN?
Summary for TEVETEN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 150 |
| Clinical Trials: | 3 |
| Patent Applications: | 4,418 |
| DailyMed Link: | TEVETEN at DailyMed |
Recent Clinical Trials for TEVETEN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| author! et al. BV | Phase 3 |
| Synexus | Phase 3 |
| Quintiles, Inc. | Phase 3 |
Paragraph IV (Patent) Challenges for TEVETEN
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| TEVETEN | Tablets | eprosartan mesylate | 400 mg and 600 mg | 020738 | 1 | 2010-05-10 |
US Patents and Regulatory Information for TEVETEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | TEVETEN | eprosartan mesylate | TABLET;ORAL | 020738-004 | Dec 22, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | TEVETEN HCT | eprosartan mesylate; hydrochlorothiazide | TABLET;ORAL | 021268-001 | Nov 1, 2001 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | TEVETEN | eprosartan mesylate | TABLET;ORAL | 020738-005 | Dec 22, 1997 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | TEVETEN | eprosartan mesylate | TABLET;ORAL | 020738-006 | May 27, 1999 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | TEVETEN HCT | eprosartan mesylate; hydrochlorothiazide | TABLET;ORAL | 021268-002 | Nov 1, 2001 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TEVETEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | TEVETEN | eprosartan mesylate | TABLET;ORAL | 020738-004 | Dec 22, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | TEVETEN | eprosartan mesylate | TABLET;ORAL | 020738-005 | Dec 22, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | TEVETEN | eprosartan mesylate | TABLET;ORAL | 020738-006 | May 27, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | TEVETEN | eprosartan mesylate | TABLET;ORAL | 020738-006 | May 27, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | TEVETEN | eprosartan mesylate | TABLET;ORAL | 020738-005 | Dec 22, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | TEVETEN | eprosartan mesylate | TABLET;ORAL | 020738-004 | Dec 22, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TEVETEN
See the table below for patents covering TEVETEN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Poland | 285590 | ⤷ Sign Up | |
| Australia | 9178291 | ⤷ Sign Up | |
| Australia | 2475692 | ⤷ Sign Up | |
| Hungary | 225048 | METANESULFONATE OF IMIDAZOLYL-PROPENOIC ACID, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR PRODUCING THEM | ⤷ Sign Up |
| Austria | 177634 | ⤷ Sign Up | |
| Poland | 290124 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TEVETEN
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0565634 | 06C0030 | France | ⤷ Sign Up | PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607 |
| 0403159 | C300006 | Netherlands | ⤷ Sign Up | PRODUCT NAME: EPROSARTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET MESYLAAT; NAT. REGISTRATION NO/DATE: RVG 22258 - RVG 22260 19980106; FIRST REGISTRATION: DE 39573.00.00 - 39573.00.00 19970417 |
| 0403159 | 14/2000 | Austria | ⤷ Sign Up | PRODUCT NAME: EPROSARTAN, AUCH IN FORM PHARMAZEUTISCH VERTRAEGLICHER SALZE WIE EPROSARTAN MESYLAT; NAT. REGISTRATION NO/DATE: 1-22115, 1-22114, 1-22117 19970930; FIRST REGISTRATION: DE 39573.00.00 - 39573.02.00 19970417 |
| 0565634 | 300115 | Netherlands | ⤷ Sign Up | |
| 0403159 | SPC/GB00/010 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: EPROSARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT INCLUDING EPROSARTAN MESYLATE; REGISTERED: DE 39 573.00.00 19970417; DE 39 573.01.00 19970417; DE 39 573.02.00 19970417; UK PL00512/0162 19990823; UK PL00512/0163 19990823; UK PL00512/0164 19990823 |
| 0565634 | C300115 | Netherlands | ⤷ Sign Up | PRODUCT NAME: EPROSARTANUM DESGEWENST IN DE VORM VAN EEN; NAT. REGISTRATION NO/DATE: RVG 25926 20020905; FIRST REGISTRATION: RVG 25926 20020905 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
